Evidence map›Paper›PMID 41354801›Full record

ArticleJournal of nanobiotechnology2025

Recruiting T-cells toward the brain for enhanced glioblastoma chemo-immunotherapy efficacy by co-delivery of cytokines and temozolomide via ultrasound-gated redox-responsive extracellular vesicles.

Lei Dong, Qing Xu, Hanjiao Liu, Ran Li, Zhengcheng Yun, Huijie Yang, Ziyan Gu, Junfan Wei, Haochun Guo, Zhanhai Wei and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lei Dong *Department of Oncology, Medical School, Zhongda Hospital, Southeast University, 87 Dingjiaqiao, Nanjing, 210009, China.
Qing Xu *Department of Radiology, Peking University Shenzhen Hospital, Shenzhen, 518036, China.
Hanjiao Liu *Department of Nursing, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, China.
Ran LiDepartment of Ultrasound, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, 453199, China.
Zhengcheng YunDepartment of Oncology, Medical School, Zhongda Hospital, Southeast University, 87 Dingjiaqiao, Nanjing, 210009, China.
Huijie YangXinxiang Key Laboratory of Tumor Migration and Invasion Precision Medicine, School of Medical Technology, Xinxiang Medical University, Xinxiang, 453003, Henan Province, P.R. China.
Ziyan GuDepartment of Oncology, Medical School, Zhongda Hospital, Southeast University, 87 Dingjiaqiao, Nanjing, 210009, China.
Junfan WeiDepartment of Nursing, Nanjing Central Hospital, 116 Chengxian Street, Nanjing, 210000, China.
Haochun GuoDepartment of Oncology, Medical School, Zhongda Hospital, Southeast University, 87 Dingjiaqiao, Nanjing, 210009, China.
Zhanhai WeiDepartment of Oncology, Medical School, Zhongda Hospital, Southeast University, 87 Dingjiaqiao, Nanjing, 210009, China.
Haijun ZhangDepartment of Oncology, Medical School, Zhongda Hospital, Southeast University, 87 Dingjiaqiao, Nanjing, 210009, China. haijunzhang@seu.edu.cn.

Funding

Henan Medical Science and Technology Research Program LHGJ20210527National Natural Science Foundation of China, National Major Scientific Instrument Development Project 82227808Sanming Project of Medicine in Shenzen Municipality SZZYSM202311016SEU Innovation Capability Enhancement Plan for Doctoral Students CXJH_SEU 24220The National Natural Science Foundation of China 81371678The Science and Technology Plan Project of Jiangsu Province, China BE2019716
6 · The paper itself

Abstract

The main limitation of chemo-immunotherapy in glioblastoma (GBM) is the immunosuppressive tumor microenvironment (TME) and the restricted permeability of the blood-brain barrier (BBB). Here, we engineer redox-responsive macrophage-derived extracellular vesicles (M-EVs)-based nanovesicles (TC@MEVs) co-loaded with chemokine CXC chemokine ligand 10 (CXCL10) and temozolomide (TMZ). Combined with ultrasound (US)-mediated BBB opening, TC@MEVs release CXCL10 to recruit CD8

Indexed as

Brain NeoplasmsCytokinesExtracellular VesiclesGlioblastomaImmunotherapyTemozolomideAnimalsBlood-Brain BarrierBrainCD8-Positive T-LymphocytesCell Line, TumorChemokine CXCL10HumansMacrophagesMiceMice, Inbred C57BLChemokine CXCL10CytokinesTemozolomideCD8+T cellsChemo-immunotherapyExtracellular vesiclesGlioblastomaTumor microenvironment

Identifiers

PMID41354801
PMCPMC12706992

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.